Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Camurus AB ( (SE:CAMX) ) has shared an announcement.
Camurus has reported a minor increase in its share capital after employees exercised 7,350 stock options under the company’s ESOP 2022/2026 program during December 2025, resulting in the issuance of an equivalent number of new registered shares. Following this transaction, the total number of shares and votes in Camurus rose from 59,872,834 to 59,880,184, a small dilution that reflects ongoing use of equity-based incentives to retain and motivate staff, with limited immediate impact on ownership structure but signalling continued alignment of employees with shareholder interests.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK691.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus is an international, science-led biopharmaceutical company that develops and commercializes innovative long-acting medicines for severe and chronic diseases, leveraging its proprietary FluidCrystal technology and R&D expertise. Its pipeline targets dependence, pain, cancer and endocrine disorders, and the company operates across Europe, the US and Australia, with shares listed on Nasdaq Stockholm under the ticker CAMX.
Average Trading Volume: 116,036
Technical Sentiment Signal: Hold
Current Market Cap: SEK36.3B
For an in-depth examination of CAMX stock, go to TipRanks’ Overview page.